1. Home
  2. MTA vs AKBA Comparison

MTA vs AKBA Comparison

Compare MTA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$8.12

Market Cap

766.4M

Sector

N/A

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.18

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
AKBA
Founded
1983
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
766.4M
729.1M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
MTA
AKBA
Price
$8.12
$1.18
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$9.00
$5.92
AVG Volume (30 Days)
562.5K
3.4M
Earning Date
01-01-0001
04-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
N/A
Revenue This Year
$118.89
$47.43
Revenue Next Year
$69.60
$17.65
P/E Ratio
N/A
$39.17
Revenue Growth
N/A
N/A
52 Week Low
$2.53
$1.15
52 Week High
$8.96
$4.08

Technical Indicators

Market Signals
Indicator
MTA
AKBA
Relative Strength Index (RSI) 54.49 31.93
Support Level $7.26 $1.15
Resistance Level $8.00 $1.60
Average True Range (ATR) 0.38 0.09
MACD 0.03 -0.02
Stochastic Oscillator 96.92 0.00

Price Performance

Historical Comparison
MTA
AKBA

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: